Apoptosis in response to cellular stress such as treatment with cytotoxic drugs is mediated by eector caspases (caspase-3) which can be activated by dierent initiator pathways. Here, we report on a cell type speci®c triggering of death receptor and/or mitochondrial pathways upon drug treatment. In type I cells (BJAB), both the receptor and the mitochondrial pathway were activated upon drug treatment, since blockade of either the receptor pathway by overexpression of dominant negative FADD (FADD-DN) or of the mitochondrial pathway by overexpression of Bcl-X L only partially inhibited apoptosis. Drug treatment induced formation of a FADD-and caspase-8-containing CD95 death-inducing signaling complex (DISC) in type I cells resulting in activation of caspase-8 as the most apical caspase. In contrast, in type II cells (Jurkat), apoptosis was predominantly controlled by mitochondria, since overexpression of Bcl-2 completely blocked drug-induced apoptosis, while overexpression of FADD-DN had no protective eect. In these cells, caspases including caspase-8 were activated by mitochondria-driven signaling events and no DISC was detected despite expression levels of CD95, FADD and caspase-8 proteins comparable to type I cells. Likewise, drug-induced CD95 aggregation was predominantly found in type I cells. Bid was cleaved prior to mitochondrial alterations in type I cells providing a molecular link between caspase-8 activation and mitochondrial perturbations, whereas in type II cells, Bid was cleaved downstream of mitochondria. Our ®ndings of a cell type speci®c response to cytotoxic drugs have implications for the identi®cation of molecular parameters for chemosensitivity or resistance in dierent tumor cells.
Introduction
Apoptosis pathways may be initiated through dierent entry sites, such as death receptors (receptor pathway) or mitochondria (mitochondrial pathway) resulting in cleavage and activation of eector caspases such as caspase-3 (Peter and Krammer, 1998; Thornberry and Lazebnik, 1998) . Following triggering of death receptors such as CD95, the adaptor molecule Fasassociated death domain (FADD) and the receptorproximal caspase-8 are recruited to form a deathinducing signaling complex (DISC) (Trauth et al., 1989; Oehm et al., 1992; Kischkel et al., 1995; Medema et al., 1997; Muzio et al., 1996; Chinnaiyan et al., 1996) . Upon recruitment to the DISC caspase-8 becomes activated and mediates cleavage of caspase-3 . A second pathway is initiated at the mitochondrial level (Kroemer and Reed, 2000) . Upon mitochondrial permeability transition, apoptogenic factors such as cytochrome c, apoptosis-inducing factor (AIF), caspase-2 or caspase-9 are released from mitochondria into the cytosol triggering caspase-3 activation through formation of the cytochrome c/ Apaf-1/caspase-9-containing apoptosome complex Zou et al., 1997; Li, et al., 1997; Susin et al., 1999a,b; Zou et al., 1999) . The mitochondrial pathway of apoptosis is inhibited by anti-apoptotic members of the Bcl-2 family which interfere with the relocalization of cytochrome c or AIF from mitochondria into the cytosol or with the binding of cytochrome c to Apaf-1 (Kroemer, 1997; Marzo et al., 1998a,b; Kluck et al., 1997; Yang et al., 1997; Hu et al., 1998) .
In CD95-mediated apoptosis we recently identi®ed two dierent apoptosis signaling cell types (Scadi et al., 1998) . In type I cells, caspase-8 is activated at the CD95 DISC in large quantities resulting in direct processing of caspase-3 (Scadi et al., 1998) . This step is independent of mitochondrial activation and cannot be blocked by overexpression of Bcl-2 (Scadi et al., 1998) . In type II cells, the amount of active caspase-8 generated at the DISC is limited (Scadi et al., 1998) . Apoptosis proceeds through mitochondrial perturbations and generation of active caspase-3 and -8 downstream of mitochondria and activation of both caspase-3 and -8 is blocked by overexpression of Bcl-2 (Scadi et al., 1998) . Signals originating from the CD95 receptor may be linked to mitochondria by Bid, a BH3 domain containing protein of the Bcl-2 family which assumes cytochrome-c-releasing activity upon cleavage by caspase-8 Luo et al., 1998; Bossy-Wetzel and Green, 1999; Desagher et al., 1999; Yin et al., 1999) . Bid-mediated ampli®cation of the mitochondrial ampli®cation loop is essential for CD95 sensitivity of some cell types in vitro and in vivo such as hepatocytes (Yin et al., 1999) .
Apoptosis in response to cellular stress including UV-irradiation-, g-irradiation-, c-myc-or thymidine kinase/ganciclovir-induced apoptosis has been described to be partially mediated by death receptorassociated signaling events (Beltinger et al., 1999; Reap et al., 1997; Rehemtulla et al., 1997; Aragane et al., 1998; Caricchio et al., 1998; Hueber et al., 1997) . Also, cell death induced by cytotoxic drugs used as anticancer agents has been reported to involve activation of death receptor/ligand systems such as the CD95 system (Debatin, 1997; Kaufmann and Earnshaw, 2000; Fulda et al., 1997 Fulda et al., , 1998a Fulda et al., ,b,c,d, 2000 Friesen et al., 1996 Friesen et al., , 1997 Friesen et al., , 1999 Houghton et al., 1997) . However, several reports have also shown that drug-induced apoptosis could not be blocked by putative antagonistic anti-CD95-antibodies (Eischen et al., 1997; Villunger et al., 1997; McGahon et al., 1998; Ferrari et al., 1998; Wesselborg et al., 1999; Glaser et al., 1999) . In most cases, drug-induced apoptosis was found to involve perturbations of mitochondrial functions (Fulda et al., 1998a,b; Friesen et al., 1999) . Recent data in FADD, Apaf-1 or caspase-9 knock-out mice also suggest that generation of a caspase-9-containing apoptosome complex is crucial for apoptosis triggered by cellular stress, at least in ®broblasts (Yeh et al., 1998; Hakem et al., 1998; Kuida et al., 1998; Cecconi et al., 1998; Yoshida et al., 1998; Varfolomeev et al., 1998) .
In the present study, we investigated the relative contribution of either the receptor or the mitochondrial pathway to drug-induced apoptosis using dierent cell lines previously found to exhibit a mitochondriaindependent (type I) or mitochondria-dependent (type II) CD95 pathway (Scadi et al., 1998) . The receptor pathway was blocked by overexpression of a dominant negative mutant of the receptor adaptor FADD (FADD-DN) and the mitochondrial pathway was blocked by overexpression of Bcl-2 or Bcl-X L . Our results indicate a cell type speci®c involvement of mitochondrial and/or death receptor signals in the apoptosis response of tumor cells towards treatment with anticancer drugs.
Results
In initial experiments we observed a variable degree of CD95 involvement or inhibition by Bcl-2 in druginduced apoptosis in dierent cell types. Interestingly, a pattern similar to type I (mitochondria-independent) or type II (mitochondria-dependent) cells in response to CD95 triggering was found. To analyse the relative contribution of either the receptor or the mitochondrial pathway to drug-induced apoptosis we used the prototype type I cell line BJAB or the prototype type II cell line Jurkat. In addition to the parental cells, derivative cells were used in which the receptor pathway was blocked by overexpression of FADD-DN or in which the mitochondrial pathway was blocked by overexpression of Bcl-2 or Bcl-X L which were previously reported to similarly inhibit mitochondrial dysfunctions in drug-induced apoptosis (Ibrado et al., 1996) . , Bcl-X L or Bcl-2 (*) were treated with 0.1 mg/ml doxorubicin (a) or with 1 mg/ml etoposide (b) for the indicated periods in the presence (*) or absence of 50 mM zVAD.fmk. Apoptosis was determined by FACS analysis of propidium iodide stained DNA content. Percentage of speci®c apoptosis was calculated as follows: 1006(experimental apoptosis (%) 7 spontaneous apoptosis (%) / 100% 7 spontaneous apoptosis (%)). Spontaneous apoptosis was below 12%. Data are the mean of triplicates, similar results were obtained in three separate experiments. Drug-induced apoptosis is regulated by mitochondria in both type I and type II cells, whereas death receptor signaling is only involved in type I cells
We ®rst analysed whether blocking of either the receptor or the mitochondrial pathway would interfere with apoptosis in response to treatment with cytotoxic drugs. In initial experiments dose response curves following treatment with doxorubicin or etoposide were determined and a concentration of 0.1 mg/ml doxorubicin or 1 mg/ml etoposide were was found to eciently induce apoptosis which were then used in further experiments. In BJAB cells (type I) overexpression of Bcl-X L partially inhibited doxorubicin-induced apoptosis, while overexpression of FADD-DN inhibited apoptosis up to 48 h, but lost its protective eect upon prolonged (72 h) drug exposure ( Figure 1a ). In contrast, in Jurkat cells (type II) FADD-DN had almost no inhibitory eect on doxorubicin-induced apoptosis, whereas apoptosis was eciently blocked by Bcl-2 overexpression ( Figure 1a ). In both cell types, doxorubicin-induced apoptosis was blocked by the caspase inhibitor benzyloxycarbonyl -Val -Ala -Asp -¯uoromethylketone (zVAD.fmk) (Figure 1a) . Similar results were obtained using etoposide (Figure 1b) . To investigate whether overexpression of FADD-DN, Bcl-2 or Bcl-X L aects long-term survival, cell viability was assessed following prolonged treatment with doxorubicin. In type I BJAB cells, overexpression of both FADD-DN or Bcl-X L delayed doxorubicin-induced loss of cell viability (Figure 1c ). In contrast, in type II Jurkat cells, FADD-DN had no inhibitory eect, whereas Bcl-2 overexpression provided some longterm protection (Figure 1c ). The levels of FADD-DN and Bcl-2 or Bcl-X L proteins, respectively, were comparable in BJAB and in Jurkat cells (data not shown). In addition, CD95-induced apoptosis was blocked in the FADD-DN cells and staurosporineinduced apoptosis was blocked in cells overexpressing Bcl-2 or Bcl-X L (data not shown). Thus, in type I cells, overexpression of both FADD-DN or Bcl-X L partially blocked doxorubicin-induced apoptosis. In type II cells, however, apoptosis was only eciently inhibited by overexpression of Bcl-2, while FADD-DN had no protective eect.
The caspase cascade is initiated by caspase-8 and -9 in type I cells or by caspase-9 in type II cells
We next investigated activation of the caspase cascade by Western blot analysis. In type I BJAB cells, overexpression of FADD-DN delayed cleavage of caspase-8, -9, -3 and cleavage of PARP induced by doxorubicin (Figure 2a) . Overexpression of Bcl-X L had little eect on caspase-8 cleavage, whereas it completely blocked processing of caspase-9 and delayed cleavage of caspase-3 and poly(ADP-ribose)polymerase (PARP) (Figure 2a ). In contrast, in type II Jurkat cells, FADD-DN had no eect on the cleavage of caspases, while caspase activation was completely blocked by Bcl-2 overexpression ( Figure 2b ). In type II cells, cleavage of caspase-9 preceded cleavage of caspase-8 indicating that caspase-9 is the most apical caspase of the cascade. In both cell types, cleavage of caspases was completely blocked by the broad spectrum caspase inhibitor zVAD.fmk (Figure 2a, b) . These results suggest that in type I cells, activation of the caspase cascade is initiated both at the receptor level by caspase-8 cleavage and at the mitochondrial level by caspase-9 cleavage. Activation of caspase-8 may directly induce caspase-3 cleavage when mitochondrial function was blocked by Bcl-X L overexpression, although the eects of activated caspase-8 were strongly ampli®ed by mitochondria. In contrast, in type II cells, activation of caspases occurs downstream of mitochondria and caspase-9 is the most apical caspase of the cascade.
Drug treatment induces DISC formation in type I, but not in type II cells
Since activation of the CD95 receptor pathway by CD95 triggering has been reported to initiate formation of a DISC, we asked whether activation of the receptor pathway by cytotoxic drugs would involve DISC formation. Upon treatment with anti-APO-1 (CD95/Fas) antibody, FADD and caspase-8 were recruited to CD95 in type I BJAB cells, but not in type II Jurkat cells despite similar expression levels of FADD or caspase-8 proteins ( Figure 3a ) consistent with our previous report (Scadi et al., 1998) . In FADD-DN overexpressing BJAB cells, FADD-DN was recruited to CD95 in addition to wild-type FADD and blocked recruitment of caspase-8, whereas overexpression of Bcl-X L did not interfere with the recruitment of FADD or caspase-8 to CD95 (Figure 3a) . Following doxorubicin treatment, FADD and caspase-8 were bound to CD95 in type I BJAB cells with maximal recruitment at 12 h ( Figure 3b ). In FADD-DN overexpressing BJAB cells, FADD-DN was recruited to CD95 and inhibited recruitment of caspase-8 ( Figure 3b ). Since overexpression of FADD-DN also inhibited caspase-8 cleavage and apoptosis in these cells (Figures 1a and 2a) , cleavage of caspase-8 at the DISC might be involved in mediating druginduced apoptosis. In contrast to FADD-DN, Bcl-X L overexpression did not interfere with druginduced recruitment of FADD or caspase-8 to CD95 (Figure 3b ). In addition to immunoprecipitating the CD95 DISC by anti-CD95 antibody, recruitment of FADD and caspase-8 to CD95 was also detected by either precipitating caspase-8 or FADD. When precipitating caspase-8, FADD was found bound to caspase-8 in type I BJAB cells ( Figure 3b ). Reciprocally, when precipitating FADD, caspase-8 was bound to FADD in type I BJAB cells ( Figure 3b ). In type II cells, however, only minimal amounts of DISC-bound FADD or caspase-8 could be detected in response to doxorubicin treatment by any of the precipitation methods used (Figure 3b ). , Bcl-X L or Bcl-2 were treated with 0.1 mg/ml doxorubicin (Doxo) for the indicated periods in the presence or absence of 50 mM zVAD.fmk. Cell lysates (40 mg protein per lane) were separated by 12% SDS ± PAGE. Western blot analysis for caspase-8, -9, -3, PARP or û-actin protein was performed as described in Materials and methods. The active fragment of caspase-8 was detected at *18 kDa, the processed fragments of caspase-9 at *37 and 35 kDa, the active fragment of caspase-3 at *17 kDa and the cleaved product of PARP at *85 kDa. Expression of û-actin was used to control equal protein loading , Bcl-X L or Bcl-2 were treated with 1 mg/ml anti-APO-1 IgG3 for 15 min (a) or with 0.1 mg/ml doxorubicin (Doxo) (b), lysed for protein extraction, and proteins were further processed for immunoblotting (blot) or immunoprecipitation (I.P.). Immunoprecipitation of CD95, caspase-8 or FADD was performed using mouse anti-APO-1 IgG3 monoclonal antibody and protein A sepharose, mouse anti-caspase-8 monoclonal antibody and protein A sepharose or mouse anti-FADD monoclonal antibody and protein G sepharose. FADD was detected as non-phosphorylated or phosphorylated protein at *27 and 29 kDa, respectively
Cell type specific pathways in drug-induced apoptosis S Fulda et al tion. Under such conditions CD95 is only signi®cantly precipitated when receptors are crosslinked, whereas no receptor molecules are precipitated without CD95 aggregation, because only few antibodies bind to single receptors (Rehemtulla et al., 1997) . Using a limiting anti-CD95 concentration, crosslinked CD95 was detected upon doxorubicin treatment in a time dependent manner with maximal aggregation at 6 ± 12 h preceeding the onset of detectable apoptosis (Figure 4) . With excess antibody, non-crosslinked CD95 receptors were also found in untreated cells (Figure 4 ). CD95 aggregation was not the result of CD95 upregulation since comparable levels of CD95 protein were detected in untreated or doxorubicin-treated cells by Western blot analysis (Figure 4) . Overexpression of FADD-DN, Bcl-X L or Bcl-2 had no eect on CD95 aggregation (Figure 4 ). Some degree of CD95 aggregation was also detected in type II Jurkat cells, yet a much lower level than in type I BJAB cells (Figure 4 ), indicating that ecient CD95 aggregation correlates with DISC formation in type I cells.
Mitochondrial perturbations depend on caspase activity in type I
In type I BJAB cells, overexpression of FADD-DN initially (24 h) reduced doxorubicin-induced loss of the mitochondrial membrane potential, but lost its inhibitory function following prolonged (48 h) treatment (Figure 5a ). In type II Jurkat cells, overexpression of FADD-DN had no inhibitory eect at any time point (Figure 5b ). In addition, loss of the mitochondrial membrane potential was reduced by zVAD.fmk in type I BJAB cells, but only slightly diminished in type II Jurkat cells (Figure 5a,b) . These results suggest that in type I cells activation of mitochondria involves DISC formation and caspase activity, while activation of mitochondria in type II cells predominantly proceeds in a caspase-independent manner. In contrast, overexpression of Bcl-2 or Bcl-X L or addition of the mitochondrion-speci®c inhibitor BA eciently inhibited doxorubicin-induced loss of the mitochondrial mem- 
Discussion
Cytotoxicity induced by anticancer drugs is eventually mediated through activation of eector molecules such as caspase-3. Activation of eector caspases may be triggered by at least two dierent initiator compartments, e.g. the death receptor pathway or the mitochondrial pathway (Kaufmann and Earnshaw, 2000) . Recent evidence in knock-out mice suggest that a caspase-9/Apaf-1 containing apoptosome complex together with mitochondria-derived factors is an essential component of apoptosis mediated by cellular stress, at least in ®broblasts (Yeh et al., 1998; Hakem et al., 1998; Kuida et al., 1998; Cecconi et al., 1998; Yoshida et al., 1998; Varfolomeev et al., 1998) . In addition, the signaling pathway originating from CD95 death receptor engagement, following ligand/ receptor interaction or receptor aggregation, has been implicated in drug-induced apoptosis (Debatin, 1997; Kaufmann and Earnshaw, 2000; Fulda et al., 1997 Fulda et al., , 1998a Fulda et al., ,b,c,d, 2000 Friesen et al., 1996 Friesen et al., , 1997 Friesen et al., , 1999 Houghton et al., 1997) . While involvement of the CD95 system in apoptosis induced by cellular stress has been described in various systems, several papers also reported that drug-induced apoptosis may occur independently from CD95 receptor engagement (Eischen et al., 1997; Villunger et al., 1997; McGahon et al., 1998; Ferrari et al., 1998; Wesselborg et al., 1999; Glaser et al., 1999) . Interestingly, most of these negative experiments have been performed using Jurkat T cells (McGahon et al., 1998 , Wesselborg et al., 1999 . The discrepancies in the data would suggest a cell type speci®c participation of the dierent initiator compartments in drug-induced apoptosis.
The major molecular components of the two principal initiator pathways have been identi®ed. For the CD95 receptor pathway, multimerization of CD95 and recruitment of FADD and caspase-8 to the DISC is essential for translation of the signal from the receptor to eector molecules (Kischkel et al., 1995; Medema et al., 1997) . The critical components of the mitochondrial pathway include caspase-9, cytochrome c and AIF (Kroemer and Reed, 2000) . In addition, activation of the receptor and the mitochondrial pathway may be interconnected through molecules such as Bid Luo et al., 1998) . Here, we report that pathways originating from the CD95 death receptor or from mitochondria are activated upon treatment with anticancer drugs in a cell type speci®c way and we molecularly de®ne a type I or type II response of tumor cells towards cytotoxic drug treatment (Figure 8 ). (FADD-DN) , Bcl-X L or Bcl-2 were treated with 0.1 mg/ml doxorubicin (Doxo). Western blot analysis for Bid protein was performed as described in Figure 2 using rabbit anti-Bid polyclonal antibody. Cleaved products were detected at *15 and 14 kDa
In type I cells, treatment with cytotoxic drugs resulted in activation of both the receptor and the mitochondrial pathway, whereas in type II cells, apoptosis was predominantly regulated by mitochondria. This conclusion is supported by a number of independent pieces of evidence. First, in type I cells, drug-induced apoptosis was only partially inhibited by blockade of either the receptor pathway by overexpression of FADD-DN or by blockade of the mitochondrial pathway by overexpression of Bcl-X L . In contrast, in type II cells, drug-induced apoptosis was completely blocked by Bcl-2 overexpression, while overexpression of FADD-DN had no protective eect. Second, treatment with doxorubicin induced formation of the FADD-and caspase-8-containing CD95 DISC in type I cells, whereas no DISC formation was detected in type II cells despite expression levels of CD95, FADD and caspase-8 proteins comparable to type I cells. Next, in type I cells, caspase activation was initiated both at the receptor level by cleavage of caspase-8 and at the mitochondrial level by cleavage of caspase-9. In these cells, activation of caspase-8 at the receptor level could directly translate into cleavage of the eector caspase-3, when mitochondrial function was blocked by overexpression of Bcl-X L , although the eects of activated caspase-8 were strongly ampli®ed by mitochondria. In contrast, in type II cells, cleavage of caspases including caspase-8 occurred predominantly downstream of mitochondria and activation of the caspase cascade was initiated by cleavage of caspase-9 as the most apical caspase. Accordingly, in type I cells, the caspase inhibitor zVAD.fmk inhibited drug-induced apoptosis prior to the involvement of mitochondria, whereas in type II cells, zVAD.fmk blocked caspase activation downstream of mitochondria without inhibiting the release of cytochrome c or AIF from mitochondria. Furthermore, Bid was cleaved upstream of mitochondria in type I cells, whereas Bid cleavage occurred downstream of mitochondria in type II cells. Of note, our ®ndings were not restricted to one particular cytotoxic drug or to BJAB and Jurkat cells, but similarly found using dierent anticancer agents, e.g. doxorubicin or etoposide. In addition, treatment with doxorubicin induced DISC formation in type I SKW6.4 cells in which overexpression of Bcl-2 provided partial protection against drug-induced apoptosis, whereas no DISC formation was detected in type II CEM cells (data not shown). Thus, tumor cells can be classi®ed as prototype type I or type II cells according to their response to cytotoxic drug treatment (Figure 8) . In type I cells, drug treatment results in activation of both the receptor and the mitochondrial pathway in a parallel and/or sequential manner. Activation of the receptor pathway involves CD95 aggregation, recruitment of FADD and caspase-8 to CD95 resulting in caspase-8 cleavage at the receptor level. Caspase-8 may either directly activate eector caspases such as caspase-3 or may act indirectly by cleaving cytosolic factors such as Bid, which promotes the release of cytochrome c from mitochondria leading to activation of eector caspases. Activation of the mitochondrial pathway results in activation of eector caspases through formation of the cytochrome c/Apaf-1/ caspase-9-containing apoptosome complex. In contrast, in type II cells, apoptosis and activation of caspases are predominantly controlled by mitochondria. This classi®cation of tumor cells as prototype type I or type II cells according to their response to cytotoxic drug treatment overlap to some extent with the classi®cation of two CD95 signaling pathways. In addition, dierences between the two cell types may not only be due to dierences in apoptosis signaling, but may also re¯ect dierences in the cellular stress response to the initial damage such as damage to DNA or membranes.
Crosslinking of death receptors such as CD95 initiates activation of the receptor pathway upon drug treatment. This may involve CD95 ligand (CD95L)-dependent or CD95L-independent CD95 aggregation (Fulda et al., 2000; Beltinger et al., 1999; Reap et al., 1997; Rehemtulla et al.; 1997 , Aragane et al., 1998 Caricchio et al., 1998; Micheau et al., 1999) . Dierences in drug-induced DISC formation in type I and type II cells were partially re¯ected by dierences in CD95 receptor aggregation which was predominantly found in type I cells. CD95 aggregation did not result from drug-induced CD95 upregulation, since comparable levels of CD95 protein were detected in untreated and doxorubicin-treated cells. CD95L may trigger CD95 aggregation, since DISC-associated CD95L was detected upon drug treatment in some type I cells such as the T leukemia cell line H9 (Fulda et al., 2000) . However, as comparable levels of CD95L were detected upon drug treatment in type I BJAB cells and type II Jurkat cells (data not shown), alternative FADD, , caspase-9 (casp-9), caspase-3, Bid, cytochrome c (cytc), Bcl-2, Bcl-X L and mitochondria act in drug-induced apoptosis is shown. AIF, which has previously been shown to mediate caspase-independent death, is not included in this scheme. To indicate the relevance of dierent signaling pathways for drug-induced apoptosis dierent arrow types are used Activation of the mitochondrial pathway upon drug treatment resulted in the release of apoptogenic factors such as cytochrome c or AIF from mitochondria. Formation of a cytochrome c/Apaf-1/caspase-9 containing apoptosome complex leads to activation of eector molecules such as caspase-3 (Li et al., 1997) . Although it was initially assumed that caspase-8 acts as a proximal initiator caspase that becomes activated by its recruitment to the CD95 DISC , several reports now show that caspase-8 can also be cleaved downstream of mitochondria in a receptorindependent manner (Fulda et al., 1998b; Ferrari et al., 1998; Wesselborg et al., 1999; Slee et al., 1999) . Activation of the receptor and the mitochondrial pathway in type I cells may occur in parallel and/or sequentially or may be interconnected through molecules such as Bid Luo et al., 1998) . In CD95-triggered apoptosis, caspase-8 has been reported to cleave Bid which then assumes a cytochrome creleasing activity. Accordingly, we found Bid cleavage prior to mitochondrial alterations in drug-treated type I cells indicating that Bid may be cleaved by caspase-8 activated at the DISC thereby linking the receptor pathway to mitochondrial events. In contrast, in type II cells Bid was cleaved downstream of mitochondria. Caspase-3-cleaved Bid has recently been reported to further trigger mitochondrial perturbations thereby creating a self-ampli®cation loop (Slee et al., 2000) . Thus, Bid may promote apoptosis by connecting the caspase cascade and mitochondria through several ampli®cation loops.
These ®ndings of a cell type speci®c triggering of the receptor and/or the mitochondrial pathway may have implications for sensitivity or resistance towards anticancer drug treatment, especially in case of defective apoptosis pathways, e.g. overexpression of anti-apoptotic molecules such as Bcl-2, since treatment response may vary according to the cell type. However, since these studies were performed using cell lines which have gone through a certain selection process during establishment, these results cannot be directly translated to the clinical situation in vivo. Moreover, our ®ndings shed some light on the controversy concerning the role of the CD95 system in drug-induced apoptosis. In fact, the relative contribution and signi®cance of the CD95 pathway for apoptosis induced by anticancer drugs may depend on the cell type. The CD95 receptor pathway may therefore function as an ampli®er in the early phase of drug-induced apoptosis and may in¯uence drug sensitivity predominantly in cells that form a DISC upon cellular stress. Thus, by demonstrating a cell type speci®c activation of the receptor and/or mitochondrial pathway in response to treatment with cytotoxic drugs, these ®ndings may have implications for a tumor cell speci®c approach to modulate chemosensitivity or resistance.
Materials and methods

Drugs
Doxorubicin (Doxo; Farmitalia, Milano, Italy) or etoposide (Bristol Myers, Munich, Germany) were provided as pure substances and dissolved in sterile water prior to each experiment.
Cell culture
Vector control, Bcl-2 or FADD-DN overexpressing Jurkat cells or vector control, Bcl-X L or FADD-DN overexpressing BJAB cells were maintained in suspension culture as previously described (Scadi et al., 1998; Fulda et al., 2000; Chinnaiyan et al., 1995) . 0.5 ± 1610 5 cells/ml were cultured in 96-well-plates for determination of apoptosis or in 75 cm 2¯a sks (Falcon, Heidelberg, Germany) for protein isolation or immunoprecipitation.
Determination of apoptosis and cell viability
Cells were incubated for indicated times with doxorubicin or etoposide. Quanti®cation of DNA fragmentation was performed by¯uorescence-activated cell-sorting (FACS) analysis of propidium iodide stained nuclei as previously described (Nicoletti et al., 1991) using CELLQuest software (Becton Dickinson, Heidelberg, Germany). For determination of cell viability, cells were treated with 0.1 mg/ml doxorubicin for 4 h, washed in PBS and resuspended in fresh medium. Cell viability was determined by Trypan blue exclusion.
Inhibition of loss of mitochondrial membrane potential by caspase inhibitor zVAD.fmk or by mitochondrion-specific inhibitor bongkrekic acid (BA)
The broad spectrum tripeptide inhibitor of caspases zVAD.fmk (Enzyme Systems Products, Dublin, CA, USA) and the mitochondrion-speci®c inhibitor BA (kindly provided by Dr Duine, University of Delft, Delft, The Netherlands) were used at 50 mM.
Western blot analysis and immunoprecipitation
Western blot analysis for protein expression and immunoprecipitation of the CD95 DISC was performed as previously described (Fulda et al., 2000; Scadi et al., 1998) using mouse anti-caspase-8 monoclonal antibody C15 (1 : 10 dilution of hybridoma supernatant; Scadi et al., 1997) , mouse anti-caspase-3 monoclonal antibody (1 : 1000, Transduction Laboratories, Lexington, KY, USA), rabbit anticaspase-9 polyclonal antibody (1 : 2000), mouse anti-CD95 monoclonal antibody (1 : 1000, Transduction Laboratories), rabbit anti-PARP polyclonal antibody (1 : 10 000, Enzyme Systems Products), mouse anti-FADD monoclonal antibody (1 : 500, Transduction Laboratories), rabbit anti-Bid polyclonal antibody (1 : 1000), mouse anti-cytochrome c monoclonal antibody (1 : 10 000, PharMingen, Hamburg, Germany), rabbit anti-AIF polyclonal antibody (1 : 2000), or mouse anti-b-actin monoclonal antibody (1 : 5000, Sigma, Deisenhofen, Germany), goat anti-mouse IgG or goat antirabbit IgG (1 : 5000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by enhanced chemiluminescence (ECL, Amersham Pharmacia, Freiburg, Germany).
CD95 aggregation
CD95 aggregation was assessed as previously described (Rehemtulla et al., 1997; Fulda et al., 2000) .
Assessment of mitochondrial transmembrane potential, preparation of mitochondria and cytosolic or nuclear extracts
The cationic lipophilic¯uorochrome 3,3'-dihexyloxacarbocyanide iodide (DiOC 6 (3)) (460 ng/ml, Molecular Probes, Eugene, OR, USA) was used to measure the mitochondrial transmembrane potential (DC m ) as previously described (Fulda et al., 1998a) . Mitochondria, cytosolic or nuclear extracts were prepared and analysed as previously described (Susin et al., 1999a; Scadi et al., 1998) .
